Dolutegravir + Atripla + Abacavir/Lamivudine + Abacavir/Lamivudine Placebo + Dolutegravir placebo + Atripla placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Infection, Human Immunodeficiency Virus I
Conditions
Infection, Human Immunodeficiency Virus I
Trial Timeline
Feb 1, 2011 → Dec 3, 2015
NCT ID
NCT01263015About Dolutegravir + Atripla + Abacavir/Lamivudine + Abacavir/Lamivudine Placebo + Dolutegravir placebo + Atripla placebo
Dolutegravir + Atripla + Abacavir/Lamivudine + Abacavir/Lamivudine Placebo + Dolutegravir placebo + Atripla placebo is a phase 3 stage product being developed by Shionogi for Infection, Human Immunodeficiency Virus I. The current trial status is completed. This product is registered under clinical trial identifier NCT01263015. Target conditions include Infection, Human Immunodeficiency Virus I.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01263015 | Phase 3 | Completed |
Competing Products
20 competing products in Infection, Human Immunodeficiency Virus I